Novartis puts pressure on Roche with cheap copy of Rituxan
Add BT as a preferred sourceZurich
SWITZERLAND'S Novartis increased pressure on Roche's ageing stable of big-selling drugs on Monday by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases.
Rixathon, from Novartis's Sandoz generics unit, follows Celltrion's Truxima that secured the European Commission's blessing in February to be used against diseases including non-Hodgkin's lymphoma and rheumatoid arthritis that are now treated by Roche's Rituxan.
TRENDING NOW
Two-thirds of Sentosa Cove resales in the red, with average loss topping S$1 million since 2023
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
Vietnam seeks US$76 billion a year from capital markets to ease reliance on banks
